Biomedical subjects

H Prast

Publications and source records attributed to H Prast.

52 records · Page 3Linked to original sources

PubMed1993

Modulation by dopamine receptors of the histamine release in the rat hypothalamus.

The involvement of dopaminergic neurons of the hypothalamus in the modulation of histamine release was studied by the push-pull technique. The posterior hypothalamus of the conscious, freely moving rat was superfused with artificial cerebrospinal fluid (CSF) and the release of histamine was determined radioenzymatically in the superfusate. Agonists and antagonists of dopamine D1-, D2- and D3-receptors were dissolved in CSF and applied to the hypothalamus through the push-pull cannula. Hypothalamic superfusion with the D1-, D2- and D3-receptor agonists dopamine or R(-)-apomorphine enhanced the release rate of histamine. (+/-)-Apomorphine also enhanced the release of histamine, but to a lesser extent than did equimolar concentration of R(-)-apomorphine. The D3-agonist quinpirole inhibited the release of histamine, while the D1-receptor agonist SKF 82958 [(+-)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine] did not virtually influence the release of the neurotransmitter. On the other hand, [-]-sulpiride which predominantly blocks D2-receptors, decreased histamine release. Hypothalamic superfusion with SKF 83566 [(+-)-7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine], which seems to be a selective antagonist of D1-receptors, enhanced the release rate of histamine. These findings suggest that dopaminergic neurons of the hypothalamus influence the release of histamine from its neurons in a dual way. D2-heteroreceptors stimulate the release of histamine, while D3-heteroreceptors seem to inhibit the release of this neurotransmitter. Both types of dopamine receptors might be located presynaptically on histaminergic neurons.(ABSTRACT TRUNCATED AT 250 WORDS)

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

PubMed1993

Pulsatile release of catecholamines in the hypothalamus of conscious rats.

To investigate the patterns of catecholamine release in the brain, the hypothalamus of conscious, freely moving rats was superfused through a push-pull cannula with artificial cerebrospinal fluid and the catecholamines dopamine, noradrenaline and adrenaline were determined in the superfusate radioenzymatically. Superfusate was continuously collected in time periods of 20 min for at least 20 h. Dopamine, noradrenaline and adrenaline release rates fluctuated according to an ultradian rhythm with a frequency of 1 cycle/92 min (dopamine and noradrenaline) or 99 min (adrenaline). Additionally, the three catecholamines were released according to an ultradian rhythm with the following frequencies: noradrenaline and adrenaline 1 cycle/12 h, dopamine 1 cycle/8 h. The release rates of dopamine and adrenaline were similar during light and dark periods, while the release rate of noradrenaline in the dark period was slightly lower than that during the light period. It is concluded that in the hypothalamus of the conscious rat the release rates of dopamine, noradrenaline and adrenaline fluctuate according to two ultradian rhythms with different frequencies.

Activity Cycles↗

PubMed1992

Pulsatile release of histamine in the hypothalamus of conscious rats.

The pattern of histamine release was investigated in the hypothalamus of the conscious, freely moving rat over 20 h. Under anaesthesia, a guide cannula was stereotaxically inserted into the posterior hypothalamus. In the conscious animal, the stylet of the guide cannula was replaced by a push-pull cannula, and the hypothalamus was superfused with artificial cerebrospinal fluid. Histamine was determined radioenzymatically in the superfusate which was continuously collected in time periods of 20 min. The release rate of histamine fluctuated according to an ultradian rhythm (frequency: 1 cycle per 83 min) and a circadian rhythm with the highest release rate of histamine between 11:00 p.m. and 1:00 a.m. The release rate of histamine during darkness was higher than that during the light period. The results demonstrate that, in the brain, neuronal histamine is released according to rhythms with various frequencies.

Animals↗

PubMed1992

Nitric oxide releases acetylcholine in the basal forebrain.

In conscious rats, the basal forebrain was superfused through a push-pull cannula and the release of acetylcholine was determined in the superfusate. Superfusion with the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine, diminished the release of acetylcholine. Subsequent superfusion with the NO donor, 3-morpholino-sydnonimine, enhanced the release of the neurotransmitter. It is concluded that endogenous NO enhances the release of acetylcholine from its neurons.

Acetylcholine↗

PubMed1992

Release of endogenous acetylcholine in the hypothalamus of conscious rats.

The release of endogenous acetylcholine was investigated by the push-pull technique. The posterior hypothalamus of conscious rats was superfused through a push-pull cannula with artificial cerebrospinal fluid (ACSF) which contained 1 mumol/l neostigmine. Acetylcholine was determined in the superfusate by high pressure liquid chromatography and electrochemical detection. Hypothalamic superfusion with potassium-rich (100 mmol/l) ACSF led to a pronounced increase in the release rate of acetylcholine. Tetrodotoxin (1 mumol/l) almost abolished the basal release of the neurotransmitter. Superfusion of the hypothalamus with atropine (10 or 50 mumol/l) led to a concentration-dependent increase, whereas superfusion with oxotremorine (50 mumol/l) inhibited the release rate of acetylcholine. It is concluded that acetylcholine released into the superfusate of the hypothalamus originates from cholinergic neurons. Furthermore, the release of acetylcholine seems to be modulated by muscarinic acetylcholine receptors, probably located on cholinergic neurons of the hypothalamus.

Acetylcholine↗

PubMed1991

In vivo modulation of the histamine release in the hypothalamus by adrenoreceptor agonists and antagonists.

The modulation of the histamine release from histaminergic neurons by noradrenergic neurons was investigated by the push-pull technique. The posterior hypothalamus of the conscious, freely moving rat was superfused with artificial CSF through a push-pull cannula and the release of endogenous histamine was determined in the superfusate. Hypothalamic superfusion with a potassium-rich CSF enhanced the release rate of histamine. Superfusion with the alpha 2-agonists noradrenaline or clonidine diminished the release rate of histamine. Moreover, clonidine abolished the potassium-induced increase in the histamine release. Superfusion with the alpha 2-antagonists yohimbine or idazoxan enhanced the release rate of histamine. It is concluded that noradrenaline released from noradrenergic neurons of the hypothalamus modulates the release of histamine from histaminergic neurons by stimulating alpha 2-adrenoreceptors located on histaminergic nerve terminals.

Adrenergic alpha-Agonists↗

PubMed1991

Does brain histamine contribute to the development of hypertension in spontaneously hypertensive rats?

Histaminergic neurons of the brain have been implicated in genetic hypertension. We investigated the effect of inhibition of histamine synthesis by alpha-fluoromethylhistidine (alpha-FMH), the irreversible inhibitor of histidine decarboxylase, on the development and maintenance of hypertension in spontaneously hypertensive rats. Young (3-week-old) and adult (7-week-old) rats were treated with alpha-fluoromethylhistidine for 29 and 13 days, respectively. Treatment of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats with alpha-fluoromethylhistidine led to a pronounced decrease in the histidine decarboxylase activity and in the histamine concentration in the brain (hypothalamus, brainstem, cortex-midbrain). In adult spontaneously hypertensive rats, the development of hypertension was not influenced by alpha-fluoromethylhistidine. In young spontaneously hypertensive rats, alpha-fluoromethylhistidine led to a transient delay in the development of hypertension which was followed by a transient tendency to increased blood pressure. It is concluded that histaminergic neurons of the brain play only a subordinate role, if any at all, in the development of hypertension in spontaneously hypertensive rats.

Animals↗

PubMed1991

Patterns of histamine release in the brain.

The pattern of histamine release has been investigated in various brain areas of anaesthetized cats and conscious, freely moving rats by the push-pull technique. In the hypothalamus, medial amygdaloid nucleus and mamillary body of the anaesthetized cat, histamine was found to be released according to an ultradian rhythm with a frequency of 1 cycle per 1-2 h. Additionally, oscillations have been observed in the medial amygdaloid nucleus and mamillary body with a frequency of 1 oscillation per 10 min. In the posterior hypothalamus of the conscious rat, histamine is also released rhythmically with a frequency of 1 cycle per 1.5 h. Moreover, the release rate of histamine is increased in the night.

Amygdala↗

PubMed1991

Inhibition of histamine synthesis influences the development of hypertension in spontaneously hypertensive rats.

Young (3-week old) and adult (7-week old) spontaneously hypertensive rats (SHR) and normotensive rats (WKY) were treated with alpha-fluoromethylhistidine (alpha-FMH) for 29 and 13 days, respectively. Treatment of SHR and WKY with alpha-FMH led to a pronounced decrease in the histidine decarboxylase activity and in the histamine concentration in all brain areas studied. In adult SHR, the development of hypertension was not influenced by alpha-FMH. In young SHR, alpha-FMH elicited a transient delay in the development of hypertension followed by a short-lasting tendency for increased blood pressure. It is concluded that histaminergic neurons of the brain play, if at all, only a secondary role in the development of hypertension in SHR.

Animals↗

PubMed1991

Influence of catecholamines on the in vivo release of histamine in the hypothalamus.

The hypothalamus of conscious, freely moving rats was superfused with artificial CSF through push-pull cannulae and the release of endogenous histamine was determined radioenzymatically in the superfusate. Superfusion with potassium chloride enhanced the release rate of histamine. The effect of potassium chloride was abolished by alpha-fluoromethylhistidine. Noradrenaline (alpha 1- and alpha 2-agonist) and clonidine (alpha 2-agonist) decreased the release rate of histamine and inhibited the potassium-induced histamine release. In preliminary experiments, yohimbine (alpha 2-antagonist) seemed to increase the release rate of histamine in the superfusate. beta-Agonists and antagonists (isoprenaline, salbutamol, propranolol) did not influence the release of histamine.

Animals↗

PubMed1989

The release of endogenous histamine in distinct brain areas is modified by electrical stimulation.

In anaesthetized cats, mamillary bodies, hypothalamic areas and medial amygdaloid nuclei were bilaterally superfused through push-pull cannulae and the effects of the electrical stimulation on the release of endogenous histamine were investigated. Electrical stimulation of the mamillary body increased the release of histamine in the stimulated area, as well as in the contralateral mamillary body. Electrical stimulation of the lateral hypothalamic area enhanced the histamine release in the contralateral hypothalamic area. Stimulation of the posterior hypothalamic area led to a delayed increase in the histamine release in the stimulated area. Stimulation of the medial amygdaloid nucleus reduced the release if histamine in the ipsilateral posterior hypothalamic area, while the histamine release in the contralateral lateral hypothalamic area was enhanced. The results demonstrate that electrical stimulation of distinct brain areas rich in histaminergic neurons may either increase, or decrease the release rate of histamine in the stimulated area and/or in remote brain areas.

Amygdala↗

PubMed1988

Pattern of in vivo release of endogenous histamine in the mamillary body and the amygdala.

The mamillary body and the medial amygdaloid nucleus of cats anaesthetized with sodium pentobarbital were bilaterally and simultaneously superfused through push-pull cannulae with CSF and the release of endogenous histamine was determined in the superfusates. Collection of the superfusates in 10 min time periods revealed that histamine was rhythmically released in the two areas with frequencies of one cycle/90 min (mamillary body) or one cycle/135 min (medial amygdaloid nucleus). Collection of the superfusates in time periods of 2 min revealed the existence of an additional ultradian rhythm with a frequency of approximately one cycle/19 min in both areas. Bilateral lesions of the suprachiasmatic nucleus did not seem to influence the pattern of histamine release in the mamillary body and the medial amygdaloid nucleus, but the rate of histamine release was decreased in the mamillary body. It is concluded that the ultradian rhythms of histamine release in the mamillary body and the medial amygdaloid nucleus are not dependent on the integrity of the suprachiasmatic nucleus. The rate of histamine release in the mamillary body seems to be under the influence of excitatory neurons which originate from the suprachiasmatic nucleus.

Activity Cycles↗

PubMed1988

Histamine, histidine decarboxylase and histamine-N-methyltransferase in brain areas of spontaneously hypertensive rats.

Histamine levels, histidine decarboxylase and histamine-N-methyltransferase activities were determined in various brain areas of young (9-week old) and adult (18-week old) normotensive rats (WKY) and hypertensive rats (SHR). When compared with WKY, histamine levels were increased in the anterior and posterior hypothalamus of young and adult SHR, as well as in the brainstem of young SHR. Histidine decarboxylase activity was unchanged in the posterior hypothalamus and in the medulla oblongata of young and adult SHR as well as in the anterior hypothalamus of young SHR, but it was slightly decreased in the anterior hypothalamus of adult SHR. Histidine decarboxylase activity was enhanced in the cortex-midbrain of young, as well as adult SHR, histamine-N-methyltransferase in the cortex-midbrain of young SHR. The following differences were found between young and adult rats: histamine levels were elevated in the cortex-midbrain of adult WKY and SHR. In the cortex-midbrain and brainstem of adult WKY and SHR histidine decarboxylase activity was also increased, while histamine-N-methyltransferase activity was elevated in the cortex-midbrain of adult WKY. The findings show changes in histamine levels, histidine decarboxylase and histamine-N-methyltransferase activities in SHR and suggest involvement of histaminergic neurons in hypertension. The activity of histaminergic neurons of adult rats seems to be higher than that of young animals.

Age Factors↗

PubMed1988

Toxic properties of the mushroom Cortinarius orellanus. I. Chemical characterization of the main toxin of Cortinarius orellanus (Fries) and Cortinarius speciosissimus (Kühn & Romagn) and acute toxicity in mice.

The toxins of the mushrooms Cortinarius orellanus (Fries) and Cortinarius speciosissimus (Kühn & Romagn) were isolated by extraction procedures and Sephadex chromatography. All intermediate and end products of the purification process were tested in mice for acute toxicity after oral and i.p. administration. In both species a fluorescent main toxin and a nonfluorescent compound of minor toxicity were found. The main toxin of both species was identified by mass spectrometric and nuclear magnetic resonance analyses as the 2,2'-bipyridine-3,3',4,4'-tetrol-1,1'-dioxide, which is identical to orellanine. The purified compound was toxic when administered either orally or i.p. When given orally the LD50 was 33 mg/kg body weight in mice. The oral LD50 of Cortinarius orellanus (2.20 g dried mushroom/kg) and of Cortinarius speciosissimus (3.12 g/kg) depended on the orellanine content (14 mg/g in Cortinarius orellanus and 9 mg/g in Cortinarius speciosissimus). The second toxic component was ineffective in mice when given orally. It caused acute toxicity when administered i.p., but toxicity was low when compared to the main toxin. Thus it appears to be of minor importance. Intraperitoneal testing of both isolated toxins and of the extract containing the whole toxic potential of the mushrooms revealed that toxicity, time dependency and expression of toxicosis is accounted for by the sum of these two toxins. No peptidic main toxin as described by other mycologists could be detected.

2,2'-Dipyridyl↗

PubMed1988

Toxic properties of the mushroom Cortinarius orellanus (Fries). II. Impairment of renal function in rats.

Oral administration of the toxic mushroom Cortinarius orellanus (Fr.) to male Sprague Dawley rats caused serious impairment of renal function. The signs observed were similar to those produced in humans who ingest this fungus. Administration of 2.0 g dried Cortinarius orellanus per kg body weight led to acute renal dysfunction within 48 h. The pattern of impairment included reduced glomerular filtration rate, decreased renal absorption of water, sodium and potassium, and proteinuria and glucosuria. The nephrotoxic effect was further characterized by decreased activities of the brush border enzymes alkaline phosphatase and gamma-glutamyltranspeptidase in urine, despite a remarkable increase in protein excretion of predominantly tubular origin. These findings were substantiated by morphologic changes, which could be detected as early as 12 h after dosing. Morphologically discernible signs of renal tubular damage start with deformation of the proximal tubular brush border region. Within 48 h after toxin ingestion, prenecrotic and necrotic cells could be found in all nephron segments contained in the renal cortex. The most prominent changes were a vesiculation of the apical cell pole and a swelling of the smooth surfaced endoplasmic reticulum and of mitochondria. The latter was accompanied by a loss in matrix material and a massive fragmentation of mitochondrial cristae membranes. Detectable quantities of the toxic principle of the mushroom, orellanine, were excreted only within the first 24 h after dosing. No impairment of liver function was detected.

Agaricales↗

PubMed1987

Investigations on the mode of action of the fungus toxin orellanine on renal cell cultures.

The effects of the fungal nephrotoxin orellanine, of 2,2'-bipyridine and of 4,4'-bipyridine on monolayers of LLPCK1-cells were tested. It is shown by the E.C.50 on growing cells that orellanine is the most toxic of the tested bipyridyls. Orellanine causes disruption of confluent monolayers and decreases the activities of membrane bound alkaline phosphatase and of cytosolic lactate dehydrogenase. Also 3H-leucine and 3H-thymidine incorporation are reduced. In contrast to this, ATP- and NADPH-levels remain constant. The cell membrane is not affected. This indicates an intracellular mechanism of action.

2,2'-Dipyridyl↗